share_log

Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022

Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022

貝利特生物公司在2022年ARVO年會上公佈了青少年STGD1中LBS-008階段1b/2研究的中期結果
Benzinga Real-time News ·  2022/05/05 08:18
  • LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects
  • A trend for stabilized or improved visual acuity was observed
  • Observed adverse events were anticipated based on the mechanism of LBS-008 action
  • STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension
  • LBS-008(又名替拉貝坦)在青少年Stargardt病(STGD1)受試者中顯示出可接受的安全性
  • 觀察到視力穩定或提高的趨勢
  • 根據LBS-008的作用機制預測觀察到的不良事件
  • 來自1b期研究的STGD1受試者現在正在參與為期2年的2期延期
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論